Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer

被引:34
作者
Kato, Yoshiyasu [1 ]
Yamada, Suguru [1 ]
Tashiro, Mitsuru [1 ]
Sonohara, Fuminori [1 ]
Takami, Hideki [1 ]
Hayashi, Masamichi [1 ]
Kanda, Mitsuro [1 ]
Kobayashi, Daisuke [1 ]
Tanaka, Chie [1 ]
Nakayama, Goro [1 ]
Koike, Masahiko [1 ]
Fujiwara, Michitaka [1 ]
Kodera, Yasuhiro [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan
关键词
PROGNOSTIC-FACTOR; CONSENSUS STATEMENT; CARCINOMA; PANCREATICODUODENECTOMY; MANAGEMENT; DIAGNOSIS; CA19-9; STAGE;
D O I
10.1016/j.hpb.2019.01.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: This study aimed to evaluate novel resectability criteria for pancreatic ductal adenocarcinoma (PDAC) proposed by the International Association of Pancreatology (IAP) by comparing them with the National Comprehensive Cancer Network (NCCN) guidelines. Methods: 369 patients who underwent upfront surgery for PDAC were retrospectively analyzed. Overall survival (OS) of each group as defined by either of the guidelines were compared and preoperative prognostic factors for OS were identified. Results: Based on the IAP-criteria, 157 patients were classified as resectable (R), 192 as borderline resectable (BR) and 20 as unresectable (UR), with the median survival time (MST) of 40 months, 17 and 11, respectively. In contrast to the NCCN-criteria, BR demonstrated significantly better OS than UR (P = 0.023) under the IAP-criteria. Performance status >= 2 (hazard ratio [HR]: 2.47, P = 0.014) and lymph node metastasis suspected by imaging (HR: 1.55, P = 0.003) were identified as independent prognostic factors by the multivariate analysis along with portal or arterial invasion, while carbohydrate antigen 19-9 >= 500 U/ml was not (HR: 1.23, P = 0.190). Conclusion: The IAP-criteria, which includes biological and conditional factors, resulted in superior separation of survival curves stratified by the resectablity when compared with the NCCN-criteria.
引用
收藏
页码:1211 / 1218
页数:8
相关论文
共 31 条
[1]   Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association [J].
Al-Hawary, Mahmoud M. ;
Francis, Isaac R. ;
Chari, Suresh T. ;
Fishman, Elliot K. ;
Hough, David M. ;
Lu, David S. ;
Macari, Michael ;
Megibow, Alec J. ;
Miller, Frank H. ;
Mortele, Koenraad J. ;
Merchant, Nipun B. ;
Minter, Rebecca M. ;
Tamm, Eric P. ;
Sahani, Dushyant V. ;
Simeone, Diane M. .
RADIOLOGY, 2014, 270 (01) :248-260
[2]  
[Anonymous], 2017, NCCN CLIN PRACTICE G
[3]   Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence [J].
Asagi, Akinori ;
Ohta, Koji ;
Nasu, Junichirou ;
Tanada, Minoru ;
Nadano, Seijin ;
Nishimura, Rieko ;
Teramoto, Norihiro ;
Yamamoto, Kazuhide ;
Inoue, Takeshi ;
Iguchi, Haruo .
PANCREAS, 2013, 42 (01) :11-19
[4]   Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma [J].
Barton, Joshua G. ;
Bois, John P. ;
Sarr, Michael G. ;
Wood, Christina M. ;
Qin, Rui ;
Thomsen, Kristine M. ;
Kendrick, Michael L. ;
Farnell, Michael B. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) :2050-2058
[5]   Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) [J].
Bockhorn, Maximilian ;
Uzunoglu, Faik G. ;
Adham, Mustapha ;
Imrie, Clem ;
Milicevic, Miroslav ;
Sandberg, Aken A. ;
Asbun, Horacio J. ;
Bassi, Claudio ;
Buechler, Markus ;
Charnley, Richard M. ;
Conlon, Kevin ;
Cruz, Laureano Fernandez ;
Dervenis, Christos ;
Fingerhutt, Abe ;
Friess, Helmut ;
Gouma, Dirk J. ;
Hartwig, Werner ;
Lillemoe, Keith D. ;
Montorsi, Marco ;
Neoptolemos, John P. ;
Shrikhande, Shailesh V. ;
Takaori, Kyoichi ;
Traverso, William ;
Vashist, Yogesh K. ;
Vollmer, Charles ;
Yeo, Charles J. ;
Izbicki, Jakob R. .
SURGERY, 2014, 155 (06) :977-988
[6]   Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].
Ferrone, Cristina R. ;
Finkelstein, Dianne M. ;
Thayer, Sarah P. ;
Muzikansky, Alona ;
Fernandez-del Castillo, Carlos ;
Warshaw, Andrew L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902
[7]   Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates [J].
Fujii, Tsutomu ;
Nakao, Akimasa ;
Yamada, Suguru ;
Suenaga, Masaya ;
Hattori, Masashi ;
Takami, Hideki ;
Inokawa, Yoshikuni ;
Kanda, Mitsuro ;
Sugimoto, Hiroyuki ;
Nomoto, Shuji ;
Murotani, Kenta ;
Kodera, Yasuhiro .
SURGERY, 2015, 157 (04) :708-715
[8]   CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy [J].
Hartwig, Werner ;
Strobel, Oliver ;
Hinz, Ulf ;
Fritz, Stefan ;
Hackert, Thilo ;
Roth, Constanze ;
Buechler, Markus W. ;
Werner, Jens .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (07) :2188-2196
[9]  
Ignacio de Ulíbarri J., 2005, Nutr. Hosp., V20, P38
[10]   International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 [J].
Isaji, Shuji ;
Mizuno, Shugo ;
Windsor, John A. ;
Bassi, Claudio ;
Fernandez-del Castillo, Carlos ;
Hackert, Thilo ;
Hayasaki, Aoi ;
Katz, Matthew H. G. ;
Kim, Sun-Whe ;
Kishiwada, Masashi ;
Kitagawa, Hirohisa ;
Michalski, Christoph W. ;
Wolfgang, Christopher L. .
PANCREATOLOGY, 2018, 18 (01) :2-11